The adjuvant Medicago uses in its vaccine is made by GlaxoSmithKline. Sponsor Message One thing the vaccine's researchers saw very little of was the fever that sometimes accompanies other COVID-19 ...

Canadian biotech firm Medicago has done the world a great service. As we reported in early March, the company developed and commercialized the world's first plant-based COVID-19 vaccine, a two-dose ...

The Canadian health regulator has accepted Medicago's application for a real-time review of its COVID-19 vaccine candidate, the drug developer said on Friday.

Medicago submits Phase 3 data to Health Canada for its plant-based COVID-19 vaccine candidate. Final portion of data submitted as part of New Drug Submission for COVID rolling review.

Medicago’s product is authorized for use in people aged 18 to 64, with Health Canada noting its effectiveness and safety in those under 18 and over 64 is still unknown.

The World Health Organization has paused the process for pre-qualification of Quebec City-based Medicago's new Covifenz shot due to its link to cigarette manufacturer Philip Morris International.

Health Canada will not make a decision on whether to authorize any vaccine under rolling review until it has ... Medicago is conducting a late-stage study of its experimental COVID-19 vaccine ...

Health Canada has accepted Medicago's application for a real-time review of its COVID-19 vaccine candidate, the drug developer said on Friday. Content. Skip to Main Content Accessibility Help.

The Canadian health regulator has accepted Medicago's application for a real-time review of its COVID-19 vaccine candidate, the drug developer said on Friday. Medicago is conducting a late-stage ...